Tuesday - December 24, 2024

Anti-Lmp2 TCR-T Cell Therapy for the Treatment of EBV-associated Cancers

2024-11-12

ALEXANDRIA, Virginia, Nov. 12 -- DUKE UNIVERSITY, Durham, North Carolina has been assigned a patent (No. US 12139523 B2, initially filed Nov. 26, 2019) developed by four inventors Xiao-Fan Wang, Durham, North Carolina; Peter Alexander, Durham, North Carolina; Qi-Jing Li, Durham, North Carolina; and Guoping Wang, Durham, North Carolina, for "Anti-LMP2 TCR-T cell therapy for the treatment of EBV-associated cancers." . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Anti-Lmp2 TCR-T Cell Therapy for the Treatment of EBV-associated Cancers

Information Request Form

Copyright Targeted News Service 2024